Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Omeros Corp (OMER), Spark Therapeutics (ONCE) and Acceleron Pharma (XLRN).
Omeros Corp (OMER)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Omeros Corp yesterday and set a price target of $32. The company’s shares opened today at $13.92.
McCarthy wrote:
“On 1/14, Omeros released 4Q18 preliminary total revenue of $22M. This is largely due to the return of separate reimbursement for Omidria in October 2018. Results of $22M suggest a record result (compared to $21.7M in 3Q17, the previous record quarter), supported in our view by record unit sales by wholesalers to ASCs (ambulatory surgical centers) and hospitals as well as a record number of purchasing hospital accounts.”
According to TipRanks.com, McCarthy is a 1-star analyst with an average return of -1.5% and a 33.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Aridis Pharmaceuticals Inc, and Adial Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Omeros Corp with a $33 average price target, representing a 137.1% upside. In a report issued on February 21, H.C. Wainwright also reiterated a Buy rating on the stock with a $34 price target.
See today’s analyst top recommended stocks >>
Spark Therapeutics (ONCE)
J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Spark Therapeutics yesterday and set a price target of $114.50. The company’s shares opened today at $113.50, close to its 52-week high of $114.20.
Kasimov observed:
“This morning’s acquisition of Spark solidifies the company’s legacy as a pioneer in the gene therapy field, in our view. Not only was Spark the first to secure US approval of a true gene therapy (Luxturna), it has also built out an increasingly broad pipeline of additional candidates across a variety of inherited orphan disorders. Initial updates for SPK-8011 for hemophilia A have fallen short of investor expectations, but it’s still early days and the breadth of the company’s platform is clearly attractive to larger companies as they jockey for position in this emerging field. We suspect this deal is as much about the breadth of Spark’s gene therapy expertise as any one individual program.”
According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 0.9% and a 42.0% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Global Blood Therapeutics, and Allogene Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Spark Therapeutics with a $94.31 average price target, which is a -16.9% downside from current levels. In a report released yesterday, Mizuho Securities also downgraded the stock to Hold with a $114.50 price target.
Acceleron Pharma (XLRN)
Cowen & Co. analyst Yaron Werber maintained a Buy rating on Acceleron Pharma yesterday and set a price target of $78. The company’s shares opened today at $43.04.
Werber has an average return of 14.8% when recommending Acceleron Pharma.
According to TipRanks.com, Werber is ranked #383 out of 5203 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Acceleron Pharma with a $71.75 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
